Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers

Table 2 Subgroup analysis of median progression-free survival

Variable	Median PFS (95%CI)	P value	Median OS (95%CI)	P value
Gender
Female	2.4 (1.6–3.6)	0.65	6.6 (4.5–9.9)	0.65
Male	2.3 (1.5–3.4)		6.9 (4.6–10.3)
Subtype of BTC
Extrahepatic cholangiocarcinoma	3.7 (1.5–18.9)	0.14	8.0 (1.8–22.3)	0.61
Intrahepatic cholangiocarcinoma	2.3 (1.9-2.8)		6.5 (4.5–9.7)
Gallbladder carcinoma	2.1 (1.8–3.7)		6.5 (5.2–10.1)
Stage at treatment with FOLFIRI
Locally Advanced	3.2 (2.0–5.2)	0.16	9.3 (5.9–14.7)	0.08
Metastatic	2.1 (1.3–3.3)		5.6 (3.5–8.8)
Line of therapy
First	3.1 (1.4–4.8)	0.24	12.3 (5.6–23.4)	0.08
Second	2.4 (1.8–3.7)		7.7 (4.9–10.5)
Third	2.3 (1.5–3.1)		5.0 (3.6–7.3)
Fourth or greater	1.5 (0.9–2.0)		7.5 (5.2–9.8)
ECOG performance status
0 or 1	2.5 (2.0–3.1)	0.44	7.7 (5.6–11.9)	0.03
2 or greater	1.5 (0.8–4.9)		2.9 (1.7–8.6)
Undocumented	2.1 (1.6–3.4)		5.3 (3.8–8.2)
Genomic analysis
KRAS
Wildtype	2.4 (1.1–5.1)	0.12	11.8 (5.5–25.4)	0.06
Mutant	3.7 (1.7–8.0)		7.5 (3.5–16.1)
FGFR
Wildtype	2.5 (1.0–6.0)	0.29	8.0 (3.3–19.4)	0.56
Fusion	4.3 (1.8–10.5)		13.4 (5.5–32.2)
IDH1
Wildtype	2.7 (1.2–6.0)	0.02	10.8 (4.9–23.9)	0.14
Mutant	2.1 (0.9–4.6)		4.1 (2.3–11.1)

BTC: Biliary tract cancer; ECOG: Eastern Cooperative Group; FOLFIRI: FOLINIC acid, 5-fluorouracil, irinotecan; OS: Overall survival; PFS: Progression-free survival.